HANGZHOU and SHAOXING, China, July 30, 2018 /PRNewswire/ -- Ascletis announced today the Ganovo® phaseIII clinical study won the top clinical research award at the 15th National Congress of Chinese Society of the Infectious Disease of the China Medical Association. Professor Wei Lai, the Director of the
Professor Wei Lai said, "This award showcased the outstanding recognition to Ganovo from the China Medical Association (CMA) and KOL's endorsement to China-driven self-innovation encouraged by the fast growth of the China bio-tech industry in recent years. As the first Direct-acting Anti-viral Agent (DAA) developed and launched successfully by a domestic company in China, Ganovo has shown excellent efficacy, better safety and tolerability. I sincerely hope Ganovo will make a larger impact and significant contribution to the elimination of HCV disease in China."
The National Congress of Chinese Society of the Infectious Disease is the largest and most influential academic conference in China. It attracted more than 2,000 experts and doctors who participated in the conference this year from July 26-29.The award further reinforces the medical community's confidence in Ganovo's excellent efficacy, better safety and tolerability, strong commitment to high quality drugs, and service to Chinese patients delivered by Ascletis as a local innovative biotech company.
View original content:http://www.prnewswire.com/news-releases/ganovo-r-phase-iii-clinical-study-won-the-top-award-at-the-infectious-disease-national-congress-of-chinese-medical-association-300688308.html
SOURCE Ascletis BioScience Co., Ltd.
Subscribe to our Free Newsletters!
Collagen plays a crucial role in glowing skin, strong nails and shiny hair. You can boost collagen ...
CRISPR technology is a simple but potent tool for editing any part of the genome (complete set of ...
FDA recently approved Mogamulizumab-kpkc, a human monoclonal antibody prescribed for adult ...View All